HomeLatest(Nasdaq:SNGX) Offers New Hope and Research for Rare Form of Non-Hodgkins Lymphoma
(Nasdaq:SNGX) Offers New Hope and Research for Rare Form of Non-Hodgkins Lymphoma
June 16, 2022 - by Editor Prism MarketView
While cutaneous T-cell lymphoma or CTCL—a rare form of non-Hodgkin’s lymphoma— currently has no FDA-approved first-line therapies, small-cap biotech Soligenix (Nasdaq: SNGX) is moving toward potential commercialization of HyBryte™ as a first-in-class treatment for the early stages of this disease that afflicts more than 25,000 patients in the United States.
HyBryte™, also known as SGX301 or synthetic hypericin, is a photodynamic therapy that uses safe visible light to treat CTCL. Unlike the traditional phototherapy of ultraviolet (UV) light for CTCL patients, HyBryte™ does not damage the skin, increase risk of skin cancer, cause wrinkling, sun damage, and/or freckles.
Dr. Ellen Kim, Medical Director of the Dermatology Clinic for the Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator (PI) for Soligenix’s positive Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in CTCL, presented key details of HyBryte’s™ efficacy and safety profile at the United States Cutaneous Lymphoma Consortium annual meeting.
In the recent interview, Dr. Kim noted that HyBryte™ is “really well tolerated. One of the limiting things we have with our current creams, ointments, and phototherapy, there are some short-term side effects, irritation, burning, sometimes blistering, and while they can be manageable, for some patients they can be really uncomfortable. HyBryte™ seems to have a very low incidence of short-term skin side effects, so probably patients will be able to stick with therapy and just feel more comfortable long-term using it, so that’s a major advantage. Then we did see good results, especially at the 16-week and 24-week time point.”
In comparison with other treatments, Dr. Kim noted that “HyBryte™ is as effective and has a better short-term, and possibly long-term, safety profile than current skin-directed therapies. It will be used both as a first-line therapy for my early-stage patients and for patients who can’t continue other therapies due to side effects or loss of response.”
HyBryte™ uses safe visible light as opposed to damaging UV light, which is the equivalent of sunlight. HyBryte™ has an advantage over phototherapy because its mechanism of action is distinct from UV phototherapy and is non-mutagenic, reducing the risk of skin damage and skin cancers, such as melanoma.
Interestingly, HyBryte™ may be a great candidate for the at-home medical market, which helps patients adhere to treatment and stay on track with their health and is expected to exceed $20.4 billion by 2027. Dr. Kim noted that a visible light panel would be safer than an UV panel at home “so it could be very well suited to home use.”
In addition, phototherapy treats the entire skin surface area exposed to the light, whereas HyBryte™ can be used for selective treatment if desired.
“After participating in the FLASH study as the overall study PI, I’ve been impressed with the efficacy and tolerability of HyBryte™— any localized skin application side effects have been very mild and manageable compared to other current skin directed therapies,” Dr. Kim added. “This will be a valuable, safer option for our patients who must utilize multiple different skin directed therapies to manage their chronic CTCL over many years and sometimes decades.”
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
This communication was produced by Prism MarketView, “PRISM”. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
“PRISM” and its affiliates are not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does “PRISM” engage in any activities that would require such registrations. “PRISM” and its affiliates do not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication.
Our articles, reports/releases and videos are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We only publish favorable information because we are compensated to publish only favorable information. We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
This communication may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, market conditions, regulatory developments, and other factors beyond the control of the profiled company. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. PRISM undertakes no obligation to update or revise any such statements.
The contributors may buy and sell securities before, during and after any particular article, report and publication. In no event shall “PRISM” or affiliates be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by “PRISM”, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages.Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. Never invest in any stock featured by “PRISM” and its affiliates unless you can afford to lose your entire investment.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org.
